MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
AlloVir Operating Cash Flow 2011-2026 | ALVR
Annual Operating Cash Flow AlloVir
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -67.7 M | -124 M | -142 M | -106 M | -60.8 M | -20.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.2 M | -142 M | -86.9 M |
Quarterly Operating Cash Flow AlloVir
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -7.44 M | - | - | - | -4.52 M | - | - | - | -32.1 M | - | -110 M | - | -46.5 M | - | -78.3 M | - | -18.9 M | - | -39.7 M | -21.7 M | -10.5 M | - | -11.3 M | -4.88 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.52 M | -110 M | -32.2 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Apellis Pharmaceuticals
APLS
|
45.3 M | $ 20.29 | -1.98 % | $ 2.56 B |  USA |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.8 | -5.3 % | $ 4.36 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 166.0 | -0.23 % | $ 8.26 B | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
181 M | $ 8.59 | -1.66 % | $ 1.4 B | Britain |
 |
Certara
CERT
|
96.3 M | $ 7.22 | 2.34 % | $ 1.16 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
209 M | $ 23.78 | -0.42 % | $ 2.91 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-23.9 M | $ 18.17 | 1.57 % | $ 873 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Eton Pharmaceuticals
ETON
|
6.82 M | $ 17.9 | -1.38 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
884 M | $ 40.5 | -1.29 % | $ 11 B | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Galectin Therapeutics
GALT
|
-41.8 M | $ 2.89 | -5.56 % | $ 180 M | USA |
 |
Capricor Therapeutics
CAPR
|
-25.6 M | $ 26.3 | -2.08 % | $ 704 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-49.4 M | $ 1.02 | -0.33 % | $ 74.9 M | USA |
 |
Galapagos NV
GLPG
|
-504 M | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
-7.27 M | $ 27.88 | 1.79 % | $ 363 M | USA |
 |
Galecto
GLTO
|
-36.9 M | $ 29.63 | -1.41 % | $ 787 M |  Danmark |
 |
Genmab A/S
GMAB
|
1.33 B | $ 27.66 | -6.71 % | $ 17.7 B | Danmark |
 |
Halozyme Therapeutics
HALO
|
652 M | $ 68.58 | -1.82 % | $ 8.22 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Hoth Therapeutics
HOTH
|
-6.98 M | $ 1.0 | -1.47 % | $ 6.38 M | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
348 M | $ 28.32 | -2.01 % | $ 1.63 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
ImmuCell Corporation
ICCC
|
358 K | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-224 M | $ 3.27 | -2.1 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-373 M | $ 28.57 | -2.16 % | $ 1.66 B | USA |
 |
Immuron Limited
IMRN
|
-3.15 M | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
|
Immatics N.V.
IMTX
|
-81.8 M | $ 10.09 | 1.0 % | $ 635 M | Germany |
 |
Immunic
IMUX
|
-85.8 M | $ 1.13 | 6.61 % | $ 176 M | USA |
 |
Immunovant
IMVT
|
-376 M | $ 27.09 | -2.38 % | $ 4.11 B | USA |
 |
Inhibrx
INBX
|
-193 M | $ 76.39 | -1.42 % | $ 3.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
-7.28 M | $ 0.8 | -2.44 % | $ 1.96 M | Canada |